The goal is to create habits that integrate seamlessly into your daily life
3 , 6 MMNST is often misdiagnosed due to its overlapping histological features with metastatic melanoma and other melanotic tumors, or it may radiographically mimic other nerve sheath tumors by exhibiting a dumbbell configuration along nerve roots
Some Southend labels list both compounds (for example, 10mg tirzepatide/5mg B6 per 0.5mL)
And when we look at conventional treatments, not all of them, but some of them, we see effects
Here's what could derail the thesis: Regulatory & Pricing Pressure Government price controls on GLP-1 drugs (Trump administration deal includes price cuts) Medicare/Medicaid coverage expansion requires discounting International pricing pressures as volumes increase Competition Intensifying Novo Nordisk fighting back with oral GLP-1 programs Amgen, Pfizer, and others entering the space Compounding pharmacies eating market share during supply shortages Operational Challenges Manufacturing constraints still limiting supply in some markets CVS formulary changes disrupted Zepbound access temporarily Volume growth partially offset by 10% lower realized prices in Q3 Valuation Risk At ~$930B market cap, expectations are sky-high Any guidance miss or pipeline disappointment will be punished severely Forward P/E of ~42 leaves little room for error Pipeline Execution Orforglipron approval timing uncertain Alzheimer's market adoption slower than hoped Clinical trial failures in crowded pipeline Smart investors acknowledge risks while staying focused on the long-term thesis
